AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 102 min read$ELV

Elevance Health Inc (ELV) Shares Surge 5.0% -- What GF Score of

Elevance Health Inc (ELV) shares rose 5.0% to $416.54 on September 10, 2026. The stock is 13.8% below its estimated fair value of $483.43, according to GF Value™. The company's GF Score™ is 90/100, with strong ratings in profitability and growth. Insiders have shown net buying of $0.5M over the past 12 months. The P/E ratio is 18.5x, slightly above its 5-year median of 17.9x.

Original reporting
gurufocus.com
Published Sep 10, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ELV
Neutral
medium confidence
Mentioned
$ELV
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ELVNeutralLow
01

Why it matters

The piece offers a valuation opinion but no new corporate event; limited trading relevance.

02

Market read

Valuation commentary with modest price move; no actionable catalyst.

03

Timing

Sep 10 2026

Relevance 4/10Novelty 2/10Timing: Sep 10 2026

Background

GuruFocus valuation snapshot for Elevance Health, noting GF Score and insider buying.

Company-level read

Ticker impact

$ELVNeutralMedium confidence
Context

Shares rose 5.0% to $416.54 on Sep 10, 2026, highlighted as undervalued versus GF fair value.

Expected impact

Limited short‑term impact unless new fundamentals emerge.

Evidence & confidence

Article repeats existing valuation data without new corporate events.

Key entities

  • company
    Elevance Health Inc

    US‑listed health insurer (ticker ELV).

Read at source← All news

Related articles

SEP 10
$ELVHighAI 8/10

Why is Elevance Health stock surging today?

Elevance Health (ELV) stock rose 5.8% to $418.21 after reaffirming its 2026 adjusted earnings guidance of at least $27.00 per share and signaling Q3 EPS is tracking ahead of expectations. The company also maintained its 2026 operating cash flow target of $6 billion and a 12% adjusted EPS growth target for 2027. Today is the ex-dividend date for its $1.72 per share quarterly dividend.

investing.com2 min
SEP 10
$ELVMedAI 8/10

Elevance holds loss ratio guidance above 90% as fall renewals near

Elevance Health reaffirmed its 2026 benefit expense ratio guidance at 90.2% (+/- 0.5%), indicating stable medical utilization and specialty pharmacy costs. The company expects to meet its adjusted earnings guidance of at least $27 per diluted share. Q2 2026 results showed an 89.7% ratio, up 0.8% YoY, driven by government business costs. Elevance, the second-largest US health insurer, processes pharmacy claims through Carelon. Steady ratio signals heavy claims payouts, impacting fall renewals.

insurancebusinessmag.com2 min
SEP 10
$ELVHighAI 8/10

Elevance Health reaffirms 2026 earnings and benefit expense guidance

Elevance Health (ELV) reaffirmed its 2026 earnings guidance of at least $20.10 per diluted share, including $6.90 in net unfavorable items, and adjusted earnings of at least $27.00 per share. The company also confirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This follows strong Q2 2026 results, with adjusted earnings of $7.45 per share and revenue of $49.8 billion, but shares faced pressure due to Medicaid concerns. Analysts have mixed price targets and ra

investing.com2 min